Low dose amiodarone in refractory tachyarrhythmias

Area of Science:

• Cardiology
• Pharmacology

Background:

• Drug-resistant tachyarrhythmias pose significant clinical challenges.
• Amiodarone is a key antiarrhythmic agent, but its use is often limited by toxicity concerns.
• Optimal dosing strategies for amiodarone in diverse patient populations require further investigation.

Purpose of the Study:

• To evaluate the efficacy and safety of a lower-dose amiodarone regimen for drug-resistant tachyarrhythmias.
• To compare the clinical outcomes of low-dose amiodarone with established western trial data.

Main Methods:

• A cohort of 50 patients with drug-resistant tachyarrhythmias (ventricular tachycardia, ventricular fibrillation, complex ventricular ectopics, supraventricular tachyarrhythmias) received amiodarone.
• Patients were treated for 6-22 months with a lower amiodarone dose compared to western trials.
• Treatment success and adverse events were monitored.

Main Results:

• High efficacy rates were observed: 81.2% for ventricular tachycardia and 88.6% for supraventricular tachyarrhythmias at 22 months.
• Amiodarone toxicity occurred in 44% of patients treated for over 12 weeks, necessitating therapy withdrawal in 4 patients.
• Clinical efficacy and onset of action were comparable to western experiences despite the lower dose.

Conclusions:

• Low-dose amiodarone demonstrates significant efficacy in managing drug-resistant tachyarrhythmias.
• The observed toxicity profile at lower doses warrants careful patient monitoring during long-term therapy.
• These findings suggest a potentially favorable risk-benefit profile for carefully selected patients requiring amiodarone treatment.